Document Detail


Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
MedLine Citation:
PMID:  2898208     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The ultrashort-acting beta blocker flestolol was studied during atrial pacing and atrial fibrillation (AF) in 10 patients with Wolff-Parkinson-White syndrome. Flestolol was given as a 100-micrograms/kg bolus followed by a 10-micrograms/kg/min infusion for 15 minutes. The drug did not alter the antegrade effective refractory period of the accessory pathway or the atrial paced cycle length at which block occurred in the accessory pathway. After flestolol, the percent of preexcited QRS complexes during AF increased (60 +/- 10 vs 87 +/- 5%, p = 0.01). Despite this, the ventricular rate slowed, with increases in mean RR interval (382 +/- 20 vs 416 +/- 22 ms, p = 0.02) and in the shortest interval between preexcited QRS complexes (251 +/- 18 vs 270 +/- 17 ms, p less than 0.01). The effect of isoproterenol 3 to 5 micrograms/min was studied in 5 patients. During atrial pacing, isoproterenol decreased the antegrade refractory period and the atrial paced cycle length of block in the accessory pathway (p less than or equal to 0.05). During AF, it decreased the percent of preexcited QRS complexes, mean RR interval and shortest interval between preexcited QRS complexes (p less than 0.05). Flestolol reversed the effects of isoproterenol both during atrial pacing and AF. Thus, flestolol does not alter conduction over the accessory pathway during atrial pacing, but during AF it slows conduction over the accessory pathway and prevents isoproterenol-mediated increases in ventricular rate. This suggests that in patients with Wolff-Parkinson-White syndrome sympathetic stimulation after the onset of AF enhances conduction over the accessory pathway and is an important determinant of ventricular rate.
Authors:
C D Swerdlow; J Peterson; L B Liem
Related Documents :
6719058 - Factors related to the progression of joint destruction in rheumatoid arthritis.
18651488 - Electrophysiological effects of single site raa pacing evaluated by means of high-gain ...
18562808 - Etiology, pathophysiology, and treatment of atrial fibrillation: part 1.
10879388 - Failure of coronary sinus pacing in reducing local atrial conduction delay in patients ...
8873668 - The asp9 asn mutation in the lipoprotein lipase gene is associated with increased progr...
11414088 - Wall stress studies of abdominal aortic aneurysm in a clinical model.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  62     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1988 Jul 
Date Detail:
Created Date:  1988-07-25     Completed Date:  1988-07-25     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  78-82     Citation Subset:  AIM; IM    
Affiliation:
Cardiac Arrhythmia Unit, Stanford University School of Medicine, California 94305.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / administration & dosage,  therapeutic use*
Adult
Atrial Fibrillation / drug therapy*,  etiology,  physiopathology
Cardiac Pacing, Artificial
Drug Therapy, Combination
Electrocardiography
Female
Fluorobenzenes*
Humans
Isoproterenol / administration & dosage,  therapeutic use
Male
Middle Aged
Propanolamines / administration & dosage,  therapeutic use*
Wolff-Parkinson-White Syndrome / complications*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Fluorobenzenes; 0/Propanolamines; 7683-59-2/Isoproterenol; 87721-62-8/flestolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of dexamethasone on electroacupuncture analgesia and central nervous system metabolism.
Next Document:  Cardiovascular pharmacology of dopexamine in low output congestive heart failure.